☆ 4.7 Review

Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer's Disease and MCI: A Review

Rammohan V. Rao et al.

Summary: Alzheimer's disease is a progressive neurodegenerative disease characterized by memory loss, personality changes, and declining cognitive function. While drugs that can slow down the progression of the disease are available, there is currently no solution to prevent or reverse the cognitive decline associated with Alzheimer's disease. Recent studies have identified various factors that contribute to the progression and severity of the disease, such as diet, lifestyle, stress, sleep, nutrient deficiencies, mental health, socialization, and toxins. Increasing evidence suggests that dietary and lifestyle changes may be effective in preventing, slowing, or reversing the progression of Alzheimer's disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Medicine, General & Internal

FDA's dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

John G. Rizk et al.

Summary: Accelerating FDA product approval based on surrogate markers without proven efficacy poses a risk of adverse outcomes for patients, even in life-threatening conditions like Alzheimer's disease. FDA's recent approval of aducanumab, despite opposition from its advisory committee and terminated efficacy trials, raises concerns about potential adverse effects and lack of clinical efficacy at high costs. A thorough review of the decision-making process is necessary to determine if it was a calculated and compassionate choice or a concerning precedent.

BMJ EVIDENCE-BASED MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Lecanemab in Early Alzheimer's Disease

Christopher H. van Dyck et al.

Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Clinical Neurology

Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies

Karen C. C. Holdridge et al.

Summary: This meta-analysis evaluated the effect of low-dose solanezumab on clinical progression in Alzheimer's disease (AD) with mild dementia. The results showed that low-dose solanezumab can slow down the clinical progression of AD.

ALZHEIMERS & DEMENTIA (2023)

Add to Collection

Review Clinical Neurology

The amyloid cascade hypothesis: an updated critical review

Kasper P. Kepp et al.

Summary: Results from recent clinical trials of anti-amyloid antibodies for Alzheimer's disease have challenged the amyloid cascade hypothesis and indicated a more complex etiology. The treatments have shown no or uncertain clinical effect on cognition, suggesting that amyloid may play a minor role in the disease. Multiple pathogenic factors may contribute to Alzheimer's disease, and evolving multi-factor disease models may lead to more effective treatment strategies.

BRAIN (2023)

Add to Collection

Review Clinical Neurology

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics

Harald Hampel et al.

Summary: Excess accumulation and aggregation of toxic amyloid-beta species in the brain is a major characteristic of Alzheimer's disease. This review comprehensively summarizes the radiological features, clinical challenges, pathophysiology, and risk factors associated with amyloid-related imaging abnormalities (ARIA) in relation to anti-amyloid monoclonal antibody treatment.

BRAIN (2023)

Add to Collection

Letter Clinical Neurology

Reply: Lecanemab: turning point, or status quo? An ethics perspective

John Hardy et al.

BRAIN (2023)

Add to Collection

Article Clinical Neurology

Lecanemab: turning point, or status quo? An ethics perspective

Timothy Daly

BRAIN (2023)

Add to Collection

Review Clinical Neurology

Hypothesis review: Alzheimer's overture guidelines

Isidro Ferrer

Summary: The diagnosis and definition of Alzheimer's disease is often based on beta-amyloid pathology, but neurofibrillary tangles appear earlier than senile plaques. In addition, the development of Alzheimer's disease is associated with multiple molecular changes and neurodegeneration during the aging process.

BRAIN PATHOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Alzheimer's Disease: An Updated Overview of Its Genetics

Jesus Andrade-Guerrero et al.

Summary: Alzheimer's disease (AD) is a common neurodegenerative disease that can be familial or sporadic. Genetic mutations in PSEN1, PSEN2, or APP are associated with familial early-onset AD, while sporadic late-onset AD is mainly linked to aging. Many polymorphisms associated with AD have been identified through GWAS. This review aims to analyze the new genetic findings related to AD pathophysiology and the mutations associated with high or low risk of developing this neurodegenerative disease identified by GWAS. Understanding genetic variability can help in early biomarker identification and the development of therapeutic targets for AD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Editorial Material Neurosciences

The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes

Kasper P. Kepp et al.

Summary: After the CLARITY-AD clinical trial results showed positive outcomes for lecanemab and supported the amyloid hypothesis, the drug was given accelerated approval by the FDA. However, there are concerns about the uncertain benefits and potential harm of lecanemab treatment for certain patients, and the data does not fully support the amyloid hypothesis. Biases from inclusion, unblinding, dropouts, and other factors are also noted. Considering the significant adverse effects and subgroup heterogeneity, it is concluded that the efficacy of lecanemab is not clinically meaningful, in line with various analyses challenging the role of amyloid-beta in Alzheimer's disease dementia.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Add to Collection

Article Immunology

The neuroprotective N-terminal amyloid-β core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models

Megan J. J. Lantz et al.

Summary: Alzheimer's disease is characterized by the accumulation of amyloid beta (Aβ) and neurofibrillary tangles, leading to chronic neuroinflammation. The N-terminal Aβ fragment and N-Aβ core have been shown to protect against neurodegeneration. This study provides evidence that these fragments can also alleviate persistent neuroinflammation in Alzheimer's disease.

JOURNAL OF NEUROINFLAMMATION (2023)

Add to Collection

Article Clinical Neurology

Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Linda Soderberg et al.

Summary: Immunotherapy targeting amyloid-beta (A ss) shows promise in treating Alzheimer's disease (AD). This study characterized the binding properties of three antibodies (lecanemab, aducanumab, and gantenerumab) to various A ss species and found different binding preferences, which may explain the variability in clinical efficacy and side effects observed for these antibodies.

NEUROTHERAPEUTICS (2023)

Add to Collection

Review Cell Biology

Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer?s disease pathology: Review and recommendations

L. Krishaa et al.

Summary: Alzheimer's disease, a neurodegenerative disorder, is influenced by the gut microbiome through the microbiota-gut-brain axis. Changes in the gut microbiome have been observed in animal models and human patients with Alzheimer's disease, impacting intestinal permeability, blood-brain barrier, neuroinflammation, and disease progression. Understanding the role of the gut microbiome in Alzheimer's disease could lead to predictive methods and potential therapies. Additionally, the comorbidity of Alzheimer's and Type 2 Diabetes Mellitus suggests shared microbiome-related treatment interventions.

MECHANISMS OF AGEING AND DEVELOPMENT (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Step by step: towards a better understanding of the genetic architecture of Alzheimer's disease

Jean-Charles Lambert et al.

Summary: Alzheimer's disease (AD) has a significant genetic component, and recent advancements in genome-wide association studies and collaborative research have improved our understanding of this component. The identification of various chromosomal regions and causal genes associated with AD risk has confirmed the involvement of major pathophysiological pathways and revealed new perspectives. Furthermore, large-scale sequencing projects have shown the impact of rare variants on AD risk. Translational research is now disseminating this knowledge, particularly through the development of genetic risk/polygenic risk scores to identify high-risk or low-risk subpopulations for AD. Further research and improvement in understanding the genetic component of AD are necessary, and genetics may ultimately redefine the boundaries and relationships between different neurodegenerative diseases.

MOLECULAR PSYCHIATRY (2023)

Add to Collection

Article Clinical Neurology

Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs A Systematic Review and Meta-analysis

Francesca Alves et al.

Summary: This study evaluates the brain volume changes caused by different subclasses of anti-beta-amyloid drugs in Alzheimer patients. The findings suggest that these drugs may accelerate brain atrophy and have varying effects on different brain regions.

NEUROLOGY (2023)

Add to Collection

Review Cell Biology

Aβ Oligomer Toxicity-Reducing Therapy for the Prevention of Alzheimer's Disease: Importance of the Nrf2 and PPARγ Pathways

Wataru Araki

Summary: Recent studies have shown that soluble amyloid-beta oligomers (A beta Os) contribute to the development of Alzheimer's disease (AD) through neurotoxic and synaptotoxic effects as well as involvement in neuroinflammation. These effects are believed to be mediated by oxidative stress. New drugs targeting A beta Os are being developed, but there is also potential for small molecules that can reduce A beta O toxicity. Specifically, molecules that enhance Nrf2 and/or PPAR gamma activity have shown promise in inhibiting A beta O toxicity. This review summarizes studies on these molecules and discusses their mechanisms in preventing A beta O-induced neurotoxicity and neuroinflammation, proposing A beta O toxicity-reducing therapy (ATR-T) as a complementary strategy for AD prevention and treatment.

CELLS (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease

Gil D. Rabinovici et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?

Jennifer J. Manly et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Ushering in a New Era of Alzheimer Disease Therapy

Eric W. Widera et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Medicine, General & Internal

Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

John R. Sims et al.

Summary: This study evaluated the efficacy and adverse events of donanemab, an antibody treatment for Alzheimer's disease. The findings showed that donanemab significantly slowed disease progression in patients with early symptomatic Alzheimer's disease.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Clinical Neurology

An insider's perspective on FDA approval of aducanumab

Yaning Wang

Summary: Aducanumab was approved under accelerated approval pathway, but there are misconceptions about the decision. Exposure-response analyses and comparisons with other compounds supported the effectiveness of aducanumab.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2023)

Add to Collection

Editorial Material Clinical Neurology

The complex pathway between amyloid β and cognition: implications for therapy

William J. Jagust et al.

Summary: For decades, the amyloid beta protein hypothesis has been the dominant theory in Alzheimer's disease research. While targeting amyloid beta has shown therapeutic benefits, its effectiveness is still unclear. The complexity of late-life cognitive impairment suggests that multiple factors, such as brain pathological changes and inflammation, may also contribute to dementia. Therefore, a new approach that considers all these factors is necessary for further research and treatment.

LANCET NEUROLOGY (2023)

Add to Collection

Review Medicine, Research & Experimental

Spontaneous and familial models of Alzheimer's disease: Challenges and advances in preclinical research

Suryapriya Ulaganathan et al.

Summary: Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder, and understanding its underlying mechanisms is still a challenge. Current animal models fail to accurately mimic the pathology of AD, both in familial and sporadic variants. This review highlights the gaps in AD models and discusses recent advancements in in vitro and chimeric AD models.

LIFE SCIENCES (2023)

Add to Collection

Article Clinical Neurology

Lecanemab Looking Before We Leap

James F. Burke et al.

Summary: Lecanemab, a novel amyloid-sequestering agent, has recently been approved for the treatment of mild dementia and mild cognitive impairment, but its benefits are small, its harms are substantial, and its costs are unprecedented.

NEUROLOGY (2023)

Add to Collection

Article Biology

Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective

Xinyue Li et al.

Science China-Life Sciences (2023)

Add to Collection

Editorial Material Medicine, Research & Experimental

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease

Markku Kurkinen

Summary: On July 6, 2023, the FDA approved Lecanemab for the treatment of Alzheimer's dementia. However, the clinical trials showed that Lecanemab did not have the expected therapeutic effects and may even have adverse effects on women and APOE4 carriers. This is disappointing news for Alzheimer's patients.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

News Item Medicine, General & Internal

Donanemab leads to modest slowing of Alzheimer's progression, study finds

Gareth Iacobucci

BMJ-BRITISH MEDICAL JOURNAL (2023)

Add to Collection

Letter Medicine, General & Internal

Lecanemab in Early Alzheimer's Disease

Bing-Syuan H. Zeng et al.

Summary: This article discusses the results of van Dyck et al.'s study in the Clarity AD trial. The primary endpoint of the study was the change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score from baseline to 18 months. The results showed a significant difference of -0.45 points in the CDR-SB score between the lecanemab and placebo groups, indicating clinical significance.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

John R. Sims et al.

Summary: This study assessed the efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. The results showed that donanemab significantly slowed the clinical progression in individuals with early symptomatic Alzheimer disease and low/medium tau pathology, as well as in the combined population with low/medium and high tau pathology.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Aducanumab-Hope or Disappointment for Alzheimer's Disease

Karolina Wojtunik-Kulesza et al.

Summary: In June 2021, the FDA approved a new drug for Alzheimer's disease called Aducanumab. This monoclonal antibody IgG1 targets amyloid beta, a main cause of Alzheimer's disease. Clinical trials have shown that Aducanumab can reduce amyloid beta and improve cognition. However, there is controversy surrounding its limitations, costs, and side effects. This review focuses on the mechanism of action of Aducanumab and discusses both the positive and negative aspects of the therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Clinical Neurology

Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Linda Soderberg et al.

Summary: The study revealed different binding profiles of lecanemab, aducanumab, and gantenerumab to various species of Aβ, which may explain the varying clinical outcomes and side effects observed for these antibodies.

NEUROTHERAPEUTICS (2023)

Add to Collection

Review Geriatrics & Gerontology

Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease

Cheng-Xin Gong et al.

Summary: Alzheimer's disease is a progressive neurodegenerative disorder that currently lacks effective treatments to slow or halt its progression. Recent changes in drug development strategy include shifting to targets other than amyloid and improving clinical trial designs. There is a growing recognition of the need for a paradigm shift towards multi-target approaches in AD drug development.

FRONTIERS IN AGING NEUROSCIENCE (2022)

Add to Collection

Article Neurosciences

The amyloid precursor protein: a converging point in Alzheimer's disease

Alexandre Delport et al.

Summary: Decades of evidence have shown the important role of amyloid precursor protein (APP) and its fragment amyloid beta (A beta) in the pathogenesis of Alzheimer's disease (AD). However, the excessive focus on A beta as the cause of AD has led to the neglect of other toxic fragments of APP as potential treatment targets. Reduction of APP and its toxic metabolites could alleviate the toxic environment associated with AD and slow disease progression.

MOLECULAR NEUROBIOLOGY (2022)

Add to Collection

Article Neurosciences

Exogenous Aβ1-42 monomers improve synaptic and cognitive function in Alzheimer's disease model mice

Yanhong Duan et al.

Summary: Growing evidence suggests a poor correlation between brain amyloid plaque and Alzheimer's disease. Reduced soluble Aβ(1-42) level is found to be the main cause of cognitive dysfunction in cDKO mice, and low soluble Aβ(1-42) level due to Aβ(1-42) deposition may also cause cognitive deficits in 3 x Tg-AD mice.

NEUROPHARMACOLOGY (2022)

Add to Collection

Review Geriatrics & Gerontology

Role of Aducanumab in the Treatment of Alzheimer?s Disease: Challenges and Opportunities

Miguel Vaz et al.

Summary: This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data, and the controversy over aducanumab approval for Alzheimer's disease (AD).

CLINICAL INTERVENTIONS IN AGING (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Astrocytes as a Therapeutic Target in Alzheimer's Disease-Comprehensive Review and Recent Developments

Mateo Rodriguez-Giraldo et al.

Summary: Astrocytes play a key role in Alzheimer's disease, with both neuroprotective and neurotoxic effects depending on the disease stage and microenvironmental factors. Therapies targeting astrocytes may be beneficial in preventing or delaying disease progression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Lecanemab for Alzheimer's disease: tempering hype and hope

The Lancet

LANCET (2022)

Add to Collection

News Item Medicine, General & Internal

Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Lecanemab for Alzheimer's disease

Sebastian Walsh et al.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Neurosciences

High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations

Andrea Sturchio et al.

Summary: This study found that high levels of soluble Aβ42 were associated with normal cognition in amyloid-positive individuals with AD-causing genetic mutations. The findings suggest that high Aβ42 may play a protective role in maintaining normal cognition.

JOURNAL OF ALZHEIMERS DISEASE (2022)

Add to Collection

Article Clinical Neurology

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease Two Phase 3 Randomized Placebo-Controlled Trials

Susanne Ostrowitzki et al.

Summary: Two phase 3 clinical trials investigated the safety and efficacy of crenezumab in participants with early Alzheimer's disease, but results showed that crenezumab, while well tolerated, did not reduce clinical decline in these patients.

JAMA NEUROLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics

Hyomin Jeong et al.

Summary: Alzheimer's disease (AD) has been mainly focused on clearing A beta plaques or preventing amyloidogenesis. However, recent evidence has shown that A beta has biological functions, such as suppressing microbial infections and regulating synaptic plasticity. Therefore, novel therapeutics targeting A beta should selectively target neurotoxic forms while preserving the physiological functions of A beta monomers.

EXPERIMENTAL NEUROBIOLOGY (2022)

Add to Collection

Review Neurosciences

(Dys)regulation of Synaptic Activity and Neurotransmitter Release by β-Amyloid: A Look Beyond Alzheimer's Disease Pathogenesis

Francesca Fagiani et al.

Summary: Beta-amyloid plays a crucial role in regulating synaptic plasticity, memory, and neurotransmitter release, beyond its well-studied role in Alzheimer's disease pathogenesis. An abnormal increase in beta-amyloid levels may lead to early defects in synaptic function and potentially contribute to the onset of neuropsychiatric symptoms in the prodromal stage of AD. Understanding the biological mechanisms underlying early synaptic alterations is essential for identifying relevant time windows for AD treatment and gaining insight into AD etiopathogenesis.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2021)

Add to Collection

Review Medicine, General & Internal

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease

Tanzil Rujeedawa et al.

Summary: Genetic and acquired Alzheimer's disease have different clinical and pathological characteristics, with Down syndrome-associated AD and Autosomal Dominant AD appearing in younger populations with a wider range of manifestations, while late-onset AD is mainly influenced by age-related comorbidities.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Editorial Material Clinical Neurology

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Jeffrey Cummings et al.

ALZHEIMERS RESEARCH & THERAPY (2021)

Add to Collection

Article Neurosciences

The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model

Kelly H. Forest et al.

Summary: The N-Aβ core can reverse impaired synaptic plasticity in hippocampal slices from 5xFAD APP/PS1 model mice, including effects on LTP and LTD, correlating with alleviation of downregulation of hippocampal AMPA-type glutamate receptors in preparations from 5xFAD mice. The action of the N-Aβ core depends on a critical di-histidine sequence and involves the phosphoinositide-3 (PI3) kinase pathway via mTOR (mammalian target of rapamycin).

FRONTIERS IN MOLECULAR NEUROSCIENCE (2021)

Add to Collection

Article Neurosciences

Soluble Amyloid-β Consumption in Alzheimer's Disease

Alberto J. Espay et al.

Summary: Brain proteins function in their soluble state, but when transformed into insoluble amyloids, their function ceases. This transformation is driven by polymerization and extrinsic factors like concentration and pH. The spread of brain amyloidosis is explained by polymerization mechanisms, rather than active replication, suggesting a loss-of-function hypothesis for pathogenicity in conditions like Alzheimer's disease. Precision medicine requires identifying the factors catalyzing protein aggregation in each individual for personalized treatment strategies.

JOURNAL OF ALZHEIMERS DISEASE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Distinct types of amyloid-beta oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease

Priyanka Madhu et al.

Summary: Soluble oligomers of Aβ play critical roles in Alzheimer's disease by causing synaptic dysfunction and memory impairments. These heterogeneous species have diverse characteristics that influence their biological effects in AD brains.

JOURNAL OF CELLULAR BIOCHEMISTRY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

Stephen Salloway et al.

Summary: Results from the phase 2/3 clinical trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease show no cognitive benefits despite reduced amyloid plaques and other key biomarkers with gantenerumab. Solanezumab did not show cognitive benefits and even led to greater decline on some measures, with no benefits on downstream biomarkers. Gantenerumab significantly reduced amyloid plaques and some biomarkers but did not slow cognitive decline in symptomatic DIAD patients.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Can we learn lessons from the FDA's approval of aducanumab?

Kathy Y. Liu et al.

Summary: The FDA recently granted accelerated approval to aducanumab for the treatment of Alzheimer disease. Here, the authors reflect on the events that led to this controversial approval and consider whether any lessons can be learned for the field.

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Editorial Material Clinical Neurology

Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease

Stephen Salloway et al.

NEUROLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab

Gil D. Rabinovici

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Revisiting FDA Approval of Aducanumab

G. Caleb Alexander et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Multidisciplinary Sciences

Treatments for Alzheimer's disease emerge

Dennis J. Selkoe

SCIENCE (2021)

Add to Collection

News Item Multidisciplinary Sciences

Alzheimer's drug approved despite murky results

Kelly Servick

SCIENCE (2021)

Add to Collection

News Item Medicine, General & Internal

Three FDA advisory panel members resign over approval of Alzheimer's drug

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Psychiatry

The need to show minimum clinically important differences in Alzheimer's disease trials

Kathy Y. Liu et al.

Summary: Deciding on the smallest change in an outcome that constitutes a clinically meaningful treatment effect is crucial in interpreting clinical trial outcomes and designing studies. While there is no consensus on MCIDs in Alzheimer's disease trials, it is important to incorporate them into clinical trials and drug development guidance.

LANCET PSYCHIATRY (2021)

Add to Collection

Article Medicine, General & Internal

High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis

Andrea Sturchio et al.

Summary: The study found that high soluble Aβ42 levels are associated with normal cognition and hippocampal volume despite increasing brain amyloidosis, suggesting that preserving high soluble Aβ42 levels could be important for maintaining cognitive function and hippocampal health.

ECLINICALMEDICINE (2021)

Add to Collection

Article Environmental Sciences

Emerging risk of environmental factors: insight mechanisms of Alzheimer's diseases

Md Ataur Rahman et al.

ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2020)

Add to Collection

Review Pharmacology & Pharmacy

Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?

Bruno Pietro Imbimbo et al.

EXPERT OPINION ON DRUG DISCOVERY (2020)

Add to Collection

Article Neurosciences

Early Effects of Aβ Oligomers on Dendritic Spine Dynamics and Arborization in Hippocampal Neurons

Carolina Ortiz-Sanz et al.

FRONTIERS IN SYNAPTIC NEUROSCIENCE (2020)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

What Is the Relevant Amyloid β42 Concentration?

Jevgenij A. Raskatov

CHEMBIOCHEM (2019)

Add to Collection

Article Neurosciences

Neuromodulatory Action of Picomolar Extracellular Aβ42 Oligomers on Presynaptic and Postsynaptic Mechanisms Underlying Synaptic Function and Memory

Walter Gulisano et al.

JOURNAL OF NEUROSCIENCE (2019)

Add to Collection

Article Cell Biology

Aβ oligomers promote oligodendrocyte differentiation and maturation via integrin β1 and Fyn kinase signaling

Tania Quintela-Lopez et al.

CELL DEATH & DISEASE (2019)

Add to Collection

Review Pharmacology & Pharmacy

Beta-amyloid short- and long-term synaptic entanglement

Cristina Lanni et al.

PHARMACOLOGICAL RESEARCH (2019)

Add to Collection

Editorial Material Cell Biology

Aβ oligomers: role at the synapse

Daniela Puzzo

AGING-US (2019)

Add to Collection

Article Clinical Neurology

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis

Gregory Klein et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

Add to Collection

Review Neurosciences

Risk factors for Alzheimer's disease

Richard A. Armstrong

FOLIA NEUROPATHOLOGICA (2019)

Add to Collection

Article Clinical Neurology

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease

Cristina Lopez Lopez et al.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)

Add to Collection

Article Medicine, General & Internal

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

Lawrence S. Honig et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Neurosciences

cAMP, cGMP and Amyloid β: Three Ideal Partners for Memory Formation

Roberta Ricciarelli et al.

TRENDS IN NEUROSCIENCES (2018)

Add to Collection

Review Clinical Neurology

Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer's disease

Gary P. Morris et al.

ACTA NEUROPATHOLOGICA (2018)

Add to Collection

Review Cell Biology

Making the final cut: pathogenic amyloid-β peptide generation by γ-secretase

Harald Steiner et al.

CELL STRESS (2018)

Add to Collection

Article Multidisciplinary Sciences

Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase

Linfeng Sun et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Add to Collection

Article Pharmacology & Pharmacy

The underexplored question of β-amyloid monomers

Agata Copani

EUROPEAN JOURNAL OF PHARMACOLOGY (2017)

Add to Collection

Article Neurosciences

Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory

Agostino Palmeri et al.

JOURNAL OF NEUROSCIENCE (2017)

Add to Collection

Article Cell Biology

Investigating the amyloid-beta enhancing effect of cGMP in neuro2a cells

Elisa Calcagno et al.

MECHANISMS OF AGEING AND DEVELOPMENT (2017)

Add to Collection

Article Clinical Neurology

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Susanne Ostrowitzki et al.

ALZHEIMERS RESEARCH & THERAPY (2017)

Add to Collection

Review Neurosciences

The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind

Roberta Ricciarelli et al.

CURRENT NEUROPHARMACOLOGY (2017)

Add to Collection

Article Clinical Neurology

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Eric R. Siemers et al.

ALZHEIMERS & DEMENTIA (2016)

Add to Collection

Review Medicine, Research & Experimental

The amyloid hypothesis of Alzheimer's disease at 25years

Dennis J. Selkoe et al.

EMBO MOLECULAR MEDICINE (2016)

Add to Collection

Article Neurosciences

Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease

Florence Pasquier et al.

JOURNAL OF ALZHEIMERS DISEASE (2016)

Add to Collection

Article Clinical Neurology

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Bengt Winblad et al.

LANCET NEUROLOGY (2016)

Add to Collection

Article Clinical Neurology

Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series

Natalie S. Ryan et al.

LANCET NEUROLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)

Add to Collection

Review Neurosciences

Alzheimer's disease due to loss of function: A new synthesis of the available data

Kasper P. Kepp

PROGRESS IN NEUROBIOLOGY (2016)

Add to Collection

Article Clinical Neurology

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies

Adrian Ivanoiu et al.

ALZHEIMERS RESEARCH & THERAPY (2016)

Add to Collection

Article Clinical Neurology

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

Rik Vandenberghe et al.

ALZHEIMERS RESEARCH & THERAPY (2016)

Add to Collection

Article Multidisciplinary Sciences

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

Mark Ultsch et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Neurosciences

Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions

Severin Filser et al.

BIOLOGICAL PSYCHIATRY (2015)

Add to Collection

Article Cell Biology

Amyloid β: Walking on the dark side of the moon

Ernesto Fedele et al.

MECHANISMS OF AGEING AND DEVELOPMENT (2015)

Add to Collection

Article Neurosciences

The case for rejecting the amyloid cascade hypothesis

Karl Herrup

NATURE NEUROSCIENCE (2015)

Add to Collection

Article Clinical Neurology

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Enchi Liu et al.

NEUROLOGY (2015)

Add to Collection

Article Clinical Neurology

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

Martin R. Farlow et al.

ALZHEIMERS RESEARCH & THERAPY (2015)

Add to Collection

Article Neurosciences

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-beta Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

Stina Tucker et al.

JOURNAL OF ALZHEIMERS DISEASE (2015)

Add to Collection

Review Cell Biology

On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis

Michael A. Castello et al.

AGEING RESEARCH REVIEWS (2014)

Add to Collection

Article Clinical Neurology

The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease

David A. Drachman

ALZHEIMERS & DEMENTIA (2014)

Add to Collection

Article Clinical Neurology

A Novel Mechanism for Cyclic Adenosine Monophosphate-Mediated Memory Formation: Role of Amyloid Beta

Roberta Ricciarelli et al.

ANNALS OF NEUROLOGY (2014)

Add to Collection

Article Neurosciences

Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury

Ahdeah Pajoohesh-Ganji et al.

BRAIN RESEARCH (2014)

Add to Collection

Article Clinical Neurology

Symptom onset in autosomal dominant Alzheimer disease A systematic review and meta-analysis

Davis C. Ryman et al.

NEUROLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Clinical Neurology

Amyloid-β and Tau The Trigger and Bullet in Alzheimer Disease Pathogenesis

George S. Bloom

JAMA NEUROLOGY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Cyclic adenosine monophosphate as an endogenous modulator of the amyloid-β precursor protein metabolism

Elisa Canepa et al.

IUBMB LIFE (2013)

Add to Collection

Article Pharmacology & Pharmacy

Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI

I. Delor et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)

Add to Collection

Article Clinical Neurology

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

Susanne Ostrowitzki et al.

ARCHIVES OF NEUROLOGY (2012)

Add to Collection

Article Neurosciences

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

Bernd Bohrmann et al.

JOURNAL OF ALZHEIMERS DISEASE (2012)

Add to Collection

Article Neurosciences

An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ

Oskar Adolfsson et al.

JOURNAL OF NEUROSCIENCE (2012)

Add to Collection

Article Clinical Neurology

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

Adam S. Fleisher et al.

LANCET NEUROLOGY (2012)

Add to Collection

Article Clinical Neurology

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Bengt Winblad et al.

LANCET NEUROLOGY (2012)

Add to Collection

Review Neurosciences

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

Iryna Benilova et al.

NATURE NEUROSCIENCE (2012)

Add to Collection

Article Clinical Neurology

Role of common and rare APP DNA sequence variants in Alzheimer disease

B. V. Hooli et al.

NEUROLOGY (2012)

Add to Collection

Article Neurosciences

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

Ronald B. DeMattos et al.

NEURON (2012)

Add to Collection

Article Clinical Neurology

Endogenous Amyloid-β is Necessary for Hippocampal Synaptic Plasticity and Memory

Daniela Puzzo et al.

ANNALS OF NEUROLOGY (2011)

Add to Collection

Article Critical Care Medicine

Detrimental Effect of Genetic Inhibition of B-Site App-Cleaving Enzyme 1 on Functional Outcome after Controlled Cortical Impact in Young Adult Mice

Rebekah C. Mannix et al.

JOURNAL OF NEUROTRAUMA (2011)

Add to Collection

Article Clinical Neurology

Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study

Natalia Acosta-Baena et al.

LANCET NEUROLOGY (2011)

Add to Collection

Article Neurosciences

Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease

Lars M. Ittner et al.

NATURE REVIEWS NEUROSCIENCE (2011)

Add to Collection

Article Neurosciences

The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology

M.L. Giuffrida et al.

REVIEWS IN THE NEUROSCIENCES (2011)

Add to Collection

Article Neurosciences

A Physiological Role for Amyloid-beta Protein: Enhancement of Learning and Memory

John E. Morley et al.

JOURNAL OF ALZHEIMERS DISEASE (2010)

Add to Collection

Article Neurosciences

Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis

Sanjay W. Pimplikar et al.

JOURNAL OF NEUROSCIENCE (2010)

Add to Collection

Article Clinical Neurology

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

Bruno Vellas et al.

CURRENT ALZHEIMER RESEARCH (2009)

Add to Collection

Article Neurosciences

β-Amyloid Monomers Are Neuroprotective

Maria Laura Giuffrida et al.

JOURNAL OF NEUROSCIENCE (2009)

Add to Collection

Article Neurosciences

Amyloid beta mediates memory formation

Ana Garcia-Osta et al.

LEARNING & MEMORY (2009)

Add to Collection

Review Biochemistry & Molecular Biology

The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases

Konstanze F. Winklhofer et al.

EMBO JOURNAL (2008)

Add to Collection

Article Neurosciences

Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus

Daniela Puzzo et al.

JOURNAL OF NEUROSCIENCE (2008)

Add to Collection

Article Medicine, General & Internal

Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial

Clive Holmes et al.

LANCET (2008)

Add to Collection

Article Neurosciences

The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease

Vilmantas Giedraitis et al.

NEUROSCIENCE LETTERS (2007)

Add to Collection

Article Psychology, Clinical

Cognitive changes in the preclinical phase of familial Alzheimer's disease

Juan Carlos Arango-Lasprilia et al.

JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY (2007)

Add to Collection

Review Clinical Neurology

Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria

Bruno Dubois et al.

LANCET NEUROLOGY (2007)

Add to Collection

Article Neurosciences

BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions

FM Laird et al.

JOURNAL OF NEUROSCIENCE (2005)

Add to Collection

Article Neurosciences

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L)

M Ramsden et al.

JOURNAL OF NEUROSCIENCE (2005)

Add to Collection

Article Clinical Neurology

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

S Gilman et al.

NEUROLOGY (2005)

Add to Collection

Article Clinical Neurology

Increased Cerebrospinal Fluid A beta 38/A beta 42 Ratio in Alzheimer Disease

Pankaj D. Mehta et al.

NEURODEGENERATIVE DISEASES (2005)

Add to Collection

Article Neurosciences

Neurogenic effect of β-amyloid peptide in the development of neural stem cells

MA López-Toledano et al.

JOURNAL OF NEUROSCIENCE (2004)

Add to Collection

Article Neurosciences

Triple-transgenic model of Alzheimer's disease with plaques and tangles:: Intracellular Aβ and synaptic dysfunction

S Oddo et al.

NEURON (2003)

Add to Collection

Review Biochemistry & Molecular Biology

Amyloid-β and τ serve antioxidant functions in the aging and Alzheimer brain

MA Smith et al.

FREE RADICAL BIOLOGY AND MEDICINE (2002)

Add to Collection

Review Biochemistry & Molecular Biology

The state versus amyloid-β:: the trial of the most wanted criminal in Alzheimer disease

CA Rottkamp et al.

PEPTIDES (2002)

Add to Collection

Article Multidisciplinary Sciences

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP

J Lewis et al.

SCIENCE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.